The FDA's CDRH Patient Engagement Advisory Committee recently met to discuss and make recommendations on factors to consider when evaluating the benefits, risks, and uncertainty of AR/VR and its use as medical devices.
It's the first and only advisory committee whose members are all patients, caregivers, and representatives of patient organizations.
Comments